Related Experiment Video

Updated: Jun 12, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Belimumab: anti-BLyS monoclonal antibody; Benlysta; BmAb; LymphoStat-B

    Drugs in R&D
    |June 1, 2010
    PubMed

    Belimumab is a fully human monoclonal antibody for the treatment of autoimmune disorders that is being developed by Human Genome Sciences and GlaxoSmithKline. Two pivotal phase III trials in systemic lupus erythematosus have been concluded with the primary endpoints being met in both studies. A phase II trial in rheumatoid arthritis has also been completed, with positive results. Marketing authorization submissions are being prepared in the major markets worldwide. This review discusses the development history and scientific profile of belimumab.

    More Related Videos

    The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice12:04

    The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

    Published on: November 1, 2015

    Isolation and Activation of Murine Lymphocytes08:08

    Isolation and Activation of Murine Lymphocytes

    Published on: October 30, 2016

    Related Concept Videos

    Hybridoma Technology01:31

    Hybridoma Technology

    Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
    Hybridoma Selection
    Commonly used fusion techniques — electroporation, polyethylene glycol...
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...